ASP Isotopes (ASPI) Projected to Post Earnings on Monday

ASP Isotopes (NASDAQ:ASPI) will likely be releasing its Q4 2025 resultson Monday, March 30th. Analysts expect ASP Isotopes to post earnings of ($0.1367) per share and revenue of $2.0310 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

ASP Isotopes Stock Down 3.4%

Shares of NASDAQ ASPI opened at $4.22 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The company has a 50-day moving average price of $6.05 and a 200-day moving average price of $7.38. The stock has a market capitalization of $467.74 million, a P/E ratio of -3.25 and a beta of 3.55. ASP Isotopes has a 1 year low of $3.92 and a 1 year high of $14.49.

Insiders Place Their Bets

In related news, COO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $5.44, for a total value of $45,902.72. Following the completion of the sale, the chief operating officer owned 1,537,817 shares of the company’s stock, valued at approximately $8,365,724.48. This trade represents a 0.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 14.40% of the company’s stock.

Hedge Funds Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in shares of ASP Isotopes in the third quarter worth about $34,000. BNP Paribas Financial Markets lifted its stake in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of ASP Isotopes by 30.4% during the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after buying an additional 1,953 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in ASP Isotopes by 96.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after buying an additional 5,353 shares during the period. Finally, Guggenheim Capital LLC bought a new position in ASP Isotopes in the 4th quarter worth approximately $72,000. Institutional investors own 16.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of ASP Isotopes in a research report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a report on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.